Scientists uncover Ebola cell-invasion strategySeptember 04, 2008Discovery could lead to therapies for deadly viral infection GALVESTON, Texas - University of Texas Medical Branch at Galveston researchers have discovered a key biochemical link in the process by which the Ebola Zaire virus infects cells - a critical step to finding a way to treat the deadly disease produced by the virus. Ebola produces severe and often fatal hemorrhagic fever in its victims and inflicts mortality rates close to 90 percent in some outbreaks. No vaccine or antiviral therapy has been developed against the virus, and it is considered a high-risk agent for bioterrorism. In addition, recent devastating outbreaks hit in Uganda in 2008 and the Democratic Republic of the Congo in 2007.
The UTMB group tied Ebola's cellular invasion mechanism to a series of biochemical reactions called the phophoinositide-3 kinase pathway (named for an enzyme found in the cell membrane). By activating the PI3 kinase pathway, they found, an Ebola virus particle tricks the cell into drawing it into a bubble-like compartment known as an endosome, which is pulled, together with the virus, into the cell. Then - at a critical point - the virus bursts free from the endosome and begins to reproduce itself. However, if the PI3 kinase pathway is shut down - as the UTMB team did with a drug designed for that purpose - Ebola virus particles can't escape from the endosome, and the disease process comes to a halt. "The nice part about identifying entry mechanisms is you can prevent the virus from infecting the cell," said UTMB microbiology and immunology associate professor Robert Davey, senior author of a paper on the investigation appearing online in the current issue of the journal PloS Pathogens. "You can stop the whole show before it even gets started." The researchers did some of their work using the Ebola Zaire virus itself, working in UTMB's Robert E. Shope, MD, Biosafety Level 4 laboratory to ensure their safety. They also conducted experiments using harmless, hollow, virus-like particles coated with the critical envelope proteins that activate the PI3 kinase pathway. Using a unique test created at UTMB that adds a light-emitting molecular beacon, called luciferase, to Ebola viruses and the virus-like particles, the investigators were able to determine exactly when and where each broke out of its bubble, and track its progress. "Up to that point, it's really a bus ride for these viruses, and PI3 kinase is the bus driver," Davey said. "Whether you're talking about Ebola or Ebola virus-like particles, they've all got the virus envelope proteins that trigger the PI3 kinase pathway, which is the first step of getting the virus onto that bus." Davey noted that while other viruses had been found that activated the PI3 kinase pathway, Ebola was the first with envelope proteins that had been seen doing so. In addition, he said, it was the first virus to be discovered interacting with the PI3 kinase pathway in order to enter cells, which could have profound implications. "It's actually triggering the reorganizing of the cell for its own devious outcomes - infecting the cell," Davey said. "But there are other possible outcomes of fiddling around with the PI3 kinase. You can get the cell to move, you can get it to live longer, all advantages for a virus. So I'm sure that this is going to be important in other viruses." In addition, a new generation of drugs are being developed that target PI3 kinase, since the enzyme is often activated in cancers. It is possible that these could also be used to defend against Ebola virus. University of Texas Medical Branch at Galveston | |||||||||||||||||||||
|
Related Ebola Current Events and Ebola News Articles UT Southwestern researchers develop new strategy for broad spectrum anti-viral drugs Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. Scientists discover new species of Ebola virus Scientists report the discovery of a new species of Ebola virus, provisionally named Bundibugyo ebolavirus, November 21 in the open-access journal PLoS Pathogens. First Holistic Guide to Primate Disease Covers Critical Gap in Global Health Why are so many infectious diseases jumping from animals to humans? Why do we have so little capacity to predict epidemics, or avoid them? 'Deadly dozen' reports diseases worsened by climate change Health experts from the Wildlife Conservation Society today released a report that lists 12 pathogens that could spread into new regions as a result of climate change, with potential impacts to both human and wildlife health and global economies. Wildlife Conservation Society discovers 'Planet of the Apes' The world's population of critically endangered western lowland gorillas received a huge boost today when the Wildlife Conservation Society released a census showing massive numbers of these secretive great apes alive and well in the Republic of Congo. Scripps research scientists reveal key structure from ebola virus Described in the July 10, 2008 issue of the journal Nature, the research reveals the shape of the Ebola virus spike protein, which is necessary for viral entry into human cells, bound to an immune system antibody acting to neutralize the virus. Vaccine for Ebola virus One of the world's deadliest diseases, caused by the Ebola virus, may finally be preventable thanks to US and Canadian researchers, who have successfully tested several Ebola vaccines in primates and are now looking to adapt them for human use. Penn scientists find a protein that inhibits Ebola from reaching out to infect neighboring cells Scientists at the University of Pennsylvania School of Veterinary Medicine have identified a protein, ISG15, that inhibits the Ebola virus from budding, the process by which viruses escape from cells and spread to infect neighboring cells. Scripps scientists studying sepsis in mice find potential drug targets for deadly disease "We have identified a key connection of signaling pathways in the cascade of events leading to sepsis. This defines a crucial point where the immune system spirals out of control to cause severe sepsis and where there is an opportunity for therapeutic intervention," says Scripps Research Professor Wolfram Ruf, who led the research with his postdoctoral fellow Frank Niessen. Combination vaccine protects monkeys from ebola and Marburg viruses An experimental, combination vaccine against Ebola and Marburg viruses using virus-like particles (VLPs) provides complete protection against infection in monkeys. More Ebola Current Events and Ebola News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||